CalciMedica Inc

CALC

Company Profile

  • Business description

    CalciMedica Inc is a clinical-stage biopharmaceutical company focused on developing therapeutics that treat serious illnesses driven by inflammatory and immunologic processes and direct cellular damage. Its product candidates act upon calcium release-activated calcium (CRAC) channels and would constitute a new class of drugs. Its product candidate is Auxora, a potent and selective intravenous formulated small molecule CRAC channel inhibitor containing the active compound zegocractin (formerly referred to as CM4620) that, in animal models, reduced acute epithelial and/or endothelial cell injury and inflammation in organs, such as the pancreas, lungs and kidneys.

  • Contact

    505 Coast Boulevard South
    Suite 307
    La JollaCA92037
    USA

    T: +1 858 952-5500

    E: [email protected]

    https://www.calcimedica.com

  • Sector

    Healthcare

    Stock type

    Defensive

  • Industry

    Biotechnology

    Fiscal Year End

    31 December 2026

    Employees

    15

Stocks News & Analysis

stocks

We remove our Moat Rating from ASX listed share

Despite a surging share price a weakening competitive position causes a reassessment of our view.
stocks

Best sustainable companies to own in 2026

We believe these companies’ strong ESG management practices give them a long-term advantage.
stocks

New data centre deal for ASX listed REIT

New parternship adds to a growing data centre pipeline in fiscal 2026.

Morningstar Investment Ideas

Markets

Index
Last price
Change
% Change
All Ordinaries9,039.202.300.03%
CAC 408,195.2145.710.56%
DAX 4024,539.3448.930.20%
Dow JONES (US)48,382.39319.100.66%
FTSE 1009,951.1419.760.20%
HKSE26,316.5521.92-0.08%
NASDAQ23,235.636.36-0.03%
Nikkei 22551,764.271,424.792.83%
NZX 50 Index13,587.2338.810.29%
S&P 5006,858.4712.970.19%
S&P/ASX 2008,734.208.200.09%
SSE Composite Index4,011.4542.611.07%

Market Movers